JACC: Basic to Translational Science (Oct 2019)

Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis of Patients With Dilated Cardiomyopathy

  • Toshiyuki Ko, MD, PhD,
  • Kanna Fujita, MD,
  • Seitaro Nomura, MD, PhD,
  • Yukari Uemura, PhD,
  • Shintaro Yamada, MD,
  • Takashige Tobita, MD,
  • Manami Katoh, MD, PhD,
  • Masahiro Satoh, MD, PhD,
  • Masamichi Ito, MD, PhD,
  • Yukako Domoto, MD, PhD,
  • Yumiko Hosoya, MD, PhD,
  • Eisuke Amiya, MD, PhD,
  • Masaru Hatano, MD, PhD,
  • Hiroyuki Morita, MD, PhD,
  • Masashi Fukayama, MD, PhD,
  • Hiroyuki Aburatani, MD, PhD,
  • Issei Komuro, MD, PhD

Journal volume & issue
Vol. 4, no. 6
pp. 670 – 680

Abstract

Read online

Summary: This study evaluated myocardial nuclear staining for the DNA damage markers poly(ADP-ribose) (PAR) and γ-H2A.X in 58 patients with dilated cardiomyopathy. Patients with left ventricular reverse remodeling (LVRR) showed a significantly smaller proportion of PAR-positive nuclei and γ-H2A.X–positive nuclei in biopsy specimens compared with those without LVRR. Propensity analysis showed that the proportion of both PAR-positive and γ-H2A.X–positive nuclei were independent prognostic factors for LVRR. In conclusion, we showed the utility of DNA damage-marker staining to predict the probability of LVRR, thus revealing a novel prognostic predictor of medical therapy for dilated cardiomyopathy. Key Words: dilated cardiomyopathy, DNA damage, left ventricular reverse remodeling, poly ADP-ribose